Analytical Data
-
基因名
EDN1
- Application
-
别名
EDN1；Endothelin-1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P05305
-
表达区间
53-73aa
-
氨基酸序列
CSCSSLMDKECVYFCHLDIIW
-
分子量
29.5kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant E.coli APX2 Protein，His
Cat：PA2000-3667
Recombinant Human DPPA5 Protein，His
Cat：PA1000-918DB
Protein Description
EDN1 (Endothelin-1) is a potent vasoconstrictor peptide that plays a crucial role in various physiological and pathological processes, including cardiovascular regulation, cellular proliferation, and inflammatory responses. Its significance is underscored by its involvement in numerous diseases such as hypertension, heart failure, and cancer. The research on EDN1 recombinant proteins has gained prominence due to their potential therapeutic applications. By producing EDN1 in a recombinant form, researchers can obtain high yields of this peptide, which allows for detailed studies of its biological effects and interactions. Additionally, the recombinant forms can be utilized in drug development and therapeutic interventions aimed at modulating endothelin signaling pathways. Understanding the structure-function relationship of EDN1 through recombinant technologies aids in the identification of specific inhibitors that can target endothelin receptors, potentially leading to novel treatments for conditions associated with endothelial dysfunction. The ongoing research not only seeks to elucidate the molecular mechanisms governing EDN1 activity but also explores its potential as a biomarker for various diseases, highlighting its importance in both basic and translational biomedical research.
